Clinical OMICS

SEP-OCT 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 4 of 51 September/October 2018 Clinical OMICs 3 Publisher & CEO MARY ANN LIEBERT President MARIANNE RUSSELL Group Publisher SANDE GIACCONE Editor in Chief CHRIS ANDERSON EVP, Strategic Development KEVIN DAVIES Commercial Director BILL LEVINE Production Editor ROBERT M. REIS Senior Editor JULIANA LEMIEUX, PH.D. Senior News Editor ALEX PHILIPPIDIS Chief Copy Editor STEVEN HERNACKI Contributing Editors CHRISTINA BENNETT, CAMILLE MOJICA REY, PH.D. Art Director JAMES LAMBO Online Product Manager SEAN HELMES Associate Director of Brand Marketing JENNIFER GATTI Online Editorial Supervisor KATHERINE VUKSANAJ Design & Layout DIANNE PAULET, BYRON DUQUE Advertising Sales Manager KAYLA MCCUTCHAN US West & Asia Pacific ( / 510-619-6988) Advertising Sales Manager REBECCA SHUMBATA US East, UK, & Europe ( 617-435-4786) List Sales SCOTT PERILLO ( / 914-740-2178) Sales Administrator FALLON MURPHY Advertising Material WANDA SANCHEZ ( Clinical OMICs Advisory Board DANIEL H. FARKAS, PH.D., HCLD Chief Clinical Laboratory Officer, Celmatix JEFFREY GIBBS, J.D. Director, Hyman, Phelps, and McNamara PETER HARRSCH, PH.D. Executive Clinical/Forensic Specialist, Waters Corp. ROGER KLEIN, M.D., J.D. Medical Director, Molecular Pathology, Cleveland Clinic JASON PARK, M.D., PH.D. Assistant Professor, Dept. of Pathology, University of Texas Southwestern Medical Center STEPHEN C. PEIPER, M.D. Professor & Chair, Dept. of Pathology, Anatomy & Cell Biology, Thomas Jefferson University AMIT RASTOGI Senior Vice President, Strategy, Growth, and Innovation, Inova DAVID SMITH, PH.D. Professor of Laboratory Medicine and Pathology, Mayo Clinic KIMBERLY STRONG, PH.D. Director, Program in Genomics and Ethics, Medical College of Wisconsin LARRY WORDEN Vice President and Senior Partner, Market Diagnostics International The views, opinions, findings, conclusions, and recommenda- tions set forth in any article in Clinical OMICs are solely those of the authors of those articles and do not necessarily reflect the views, policy, or position of Clinical OMICs, its Publisher, or its editorial staff and should not be attributed to any of them. All advertisements are subject to review by the Publisher. The acceptance of advertisements does not constitute an endorse- ment of the product or service advertised. Clinical OMICs (ISSN-2334-1351) is published online bimonthly by GEN Publishing, 140 Huguenot St., 3rd Floor, New Rochelle, NY 10801-5215. For subscription information go to: Copyright © 2018 by GEN Publishing, New Rochelle, NY I n this issue of Clinical OMICs there will be some changes you will notice right away—this editorial moving much closer to the front of the magazine is one— along with some others that might not be apparent to the eye, but will help us serve you, our readers, better. The most notable change is the elimination of virtually all of our focused sections. That means our magazine will no longer carry the Diagnos- tics, Data & Informatics, In the Lab, or Precision Medicine sections. We will continue to cover these topics, but as the past year-and-a-half has shown, as we plan the content for each issue, the individual sections provided too rigid a framework. Often, we were in the unfortunate situation of needing to publish a story of lesser importance than others, simply because we needed a topical story for one of our sections. So while it was a tidy structure and a way to communicate with our readers exactly the topics we intend to cover in our pages, it soon became apparent that it could also be an impediment to providing our readers with the best content available. This issue is the first step in a direction of providing more space for longer form journalism, more cutting edge science, technologies, and business models. It also provides more opportunity for us to publish content contributed by our readers—the scientists, physicians, and business leaders that are using omics to significantly influence and improve clinical care. While we're talking about content, it gives me great pleasure to introduce a new staff editor for Clinical OMICs, Julianna LeMieux, Ph.D. Julianna's work first graced our pages in the July–August issue in the feature "Eyeing Epigen- etic Markers," where she dove into the science of examining the methylation patterns of cell-free DNA captured in the blood to help determine a cancer 's site of origin. Julianna received her Ph.D. in molecular biology and microbiology from Tufts University School of Medicine and followed that with postdoc work at MIT while still living in Boston. Two years ago, after a change of location to the New York City area, and landing a tenure-track teaching position at a college just outside the city, Julianna switched gears to pursue what she calls "passion for science communication." This month, her work can be seen throughout Clinical OMICs, from her fea- ture examining progress in Parkinson's disease and Huntington's disease (page 12) to stories about CRISPR and the potential of some exosomes to help predict immunotherapy response (pages 34 and 37). Julianna's nose for the science, her ability to ask the right questions of the right people, and her writing talent are a most welcome addition and we look forward to her contributions in our pages. FROM THE EDITOR Chris Anderson Editor in Chief Clinical OMICs Evolves and Grows

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - SEP-OCT 2018